Skip to main content

Table 1 Patient characteristics, adverse events, and response to nivolumab treatment

From: PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation

  Patient 1 Patient 2 Patient 3
Age 47 25 55
Sex Male Male Male
Prior therapies (no.) 6 6 5
Stem cell source Matched-related Matched-related Haploidentical and umbilical cord blood
Conditioning regimen Reduced intensity Reduced intensity Reduced intensity
T cell depleted graft Yes Yes Yes
Prior GVHD No Chronic GVHD of gut Chronic oral GVHD
Days to relapse following AlloHSCT (no.) 181 2456 389
Localization and size of relapse Diffuse bone and splenic involvement Multifocal adenopathy in mediastinum, retroperitoneum and pelvis. Largest lymph node 2.3 × 1.5 cm in mediastinum Multifocal adenopathy in neck, chest, abdomen and pelvis. Largest lymph node 4.2 × 1.8 cm in right axilla
Prior DLI No Yes No
Immune-related adverse events Grade 2 Keratoconjunctivitis Grade 3 Inflammatory polyarthritis and grade 2 keratoconjunctivitis Grade 1 Rash
Response to nivolumab Partial response Partial response Partial response
Duration of response 6 Months+ 10 Months+ 14 Months+
Donor CD3+ chimerism before and after treatment 18 to 49% Not available Not available
Back to article page